A Phase 1 interventional study of KDT-3594 and Placebo in Parkinson Disease, sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-01.
Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Parkinson Disease with a site in Japan — 9 open to participants now, 10 under way, none of them phase 3. Parkinson Disease · Japan.
Among the 75 studies in Parkinson Disease with a site in Japan, this one is the 43rd largest by enrollment of the 60 interventional ones that give a count, is one of 3 that started in 2017, is one of 13 in phase 1, and was the 42nd registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →9 of the 75 studies in Parkinson Disease with a site in Japan are open now. Recruiting first, the newest first:
AbbVie · Sites in Japan, United States, Canada and 6 more countries
Ages 18–69
University of Shizuoka · Sites in Japan
Ages 18–85 · Healthy volunteers
Fujita Health University · Sites in Japan
Ages 18–80
Eli Lilly and Company · Sites in Japan, United States
Ages 30–85 · Healthy volunteers
Prevail Therapeutics · Sites in Japan, United States, Germany and 2 more countries
Ages 30–80 · Healthy volunteers
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 20 Years to 74 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 24 · Phase 3 21 · Phase 4 2
First in 2004; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is close to the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 99 across the 60 interventional studies, 432 across the 15 observational. Of the 63 that completed or were terminated, 28 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 75 have an industry lead sponsor. The 10 most frequent:
Kissei Pharmaceutical Co., Ltd. is the lead sponsor of 63 studies on the registry; 3 are open to participants now.
Kissei Pharmaceutical Co., Ltd. has 4 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Parkinson Disease with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05916157AbbVieAn Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease | 2027-01 |
| NCT07227896AbbVieReal-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 75 studies in Parkinson Disease with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study in healthy adult males is to investigate safety and pharmacokinetics of single and multiple oral doses of KDT-3594.
The purpose of this study in patients with Parkinson's disease is to investigate safety and pharmacokinetics of single and multiple oral doses of KDT-3594. The exploratory efficacy of KDT-3594 will also be investigated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy volunteer part
Patient part
Exclusion Criteria:
Healthy volunteer part
Patient part
Healthy volunteer part and patient part
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral dose of KDT-3594
Drug: KDT-3594
Multiple oral doses of KDT-3594
Drug: KDT-3594
Multiple oral doses of Placebo
Drug: Placebo
Single oral dose of KDT-3594
Drug: KDT-3594
Multiple oral doses of KDT-3594
Drug: KDT-3594
Oral administration
Oral administration
Occurrence of adverse events
Time frame: Up to 15 days after last administration
Plasma pharmacokinetic parameter of KDT-3594 and main metabolites: Cmax
Time frame: Up to 336 hours after last administration
Plasma pharmacokinetic parameter of KDT-3594 and main metabolites: AUC
Time frame: Up to 336 hours after last administration
Unified Parkinson's Disease Rating Scale (UPDRS) score (Only patient part)
Time frame: Up to 336 hours after last administration
Ran from Feb 2017 to primary completion in Aug 2018, 17 months.
Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's 17 months is above that.
Counting every sponsor, half of 204 studies reached it within 19 months; a quarter within 5 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: KDT-3594
Kissei Pharmaceutical Co., Ltd. →